Skip to main content





Our focus - Neuroscience

Neurological conditions are the third most common cause of disability and premature death in Europe.[1] We are determined to continue to increase our understanding, and society’s perception, of neurological disorders by supporting and engaging with you, the patient, through open dialogue and through championing innovative treatments.

At Janssen, we have an ambitious goal – to ensure a future where we can predict and prevent some of the world’s most devastating and debilitating nervous system disorders.

By partnering with the neuroscience community, we aim to lead the new era of neuroscience precision medicine, developing pioneering solutions to reduce the burden and disability caused by nervous system diseases.

Nervous system disorders are more common than you think

Central nervous system disorders, such as major depressive disorder, schizophrenia and multiple sclerosis (MS) are the second leading cause of death worldwide, and it is estimated that one third of people living in Europe will be affected by a neurological disorder in their lifetime.[2][3]

We are determined to continue to increase our understanding of nervous system disorders by supporting and engaging with patients, through open dialogue and innovative treatments.

Holding patients and caregivers at our core

Our ultimate responsibility remains with our patients who, alongside caregivers, are at the heart of everthing we do.

We cannot look at neuroscience through the lens of science alone. Each person’s experience of a nervous system disease is uniquely influenced by personal, medical, environmental and social factors.[4] It is essential to work in partnership with the community to understand everyday realities and ensure we make a real impact on individual lives.

This is why we work with around 30 patient and carer organisations across Europe to enhance our understanding of living with nervous system diseases. These partnerships allow us to embed their perspectives in our work and provide practical support that directly addresses previously unmet needs

Leading the way through innovation

Our medicines have improved millions of lives, changing the way we treat neuropsychiatric and neurodegenerative conditions.

We are immensely proud of the many groundbreaking therapies Janssen has pioneered over the course of our 60+ year legacy in this field. At Janssen, we are focused on pushing the boundaries of what’s possible, evolving our work and knowledge to include neurological and autoantibody-driven diseases.

We opened four Innovation Centres in major science and technology hubs throughout the world to focus on early-stage partnerships across all our key therapy areas. We also nurture innovation through our 12 Janssen Laboratories (JLABs) around the world that incubate emerging health technologies and businesses and accelerate learnings.

Our neuroscience portfolio is focused on the areas where we can make the biggest difference.

Our collaborations


Revolutionary solutions are only discovered when the best and brightest minds come together. At Janssen, we have the critical mass of diverse and world-renowned talent to advance knowledge, education and innovation through a combination of our own laboratories and creative licensing, acquisition, academic partnership and public-private partnership opportunities.

Our alliances take many forms, but our goal is always the same: to advance scientific research and deliver solutions that provide value to patients, physicians and society. We actively pursue new ways of collaborating in our core areas of interest and seek out like-minded health and technology companies to partner with.



We’re using emerging science to develop novel therapies for the treatment of severe mood disorders.

Learn more


We’ve led the way in the development of simplified and time-saving treatments for patients.

Learn more

Multiple sclerosis

We’re advancing through innovation to improve outcomes for people with serious neuropsychiatric and neurodegenerative diseases like multiple sclerosis.


“We are at the beginning of an exciting new era for treating nervous system disorders, combining our knowledge, tools and technology to push innovation forward exponentially. With more than six decades of life-changing discoveries in the field, we want to continue working with our partners to bring solutions to those affected for years to come.”

Dr. Tamara Werner-Kiechle

EMEA Therapeutic Area Lead, Central Nervous System & Pulmonary Hypertension


Approximately 40 million people across the EU are living with depression.[5] It’s the leading cause of disability and disease burden worldwide according to the World Health Organization, with a high unmet need.[6] Which means there is a lot more work to be done.

Achieving response and remission with treatment in major depressive disorder (MDD) requires time and effort, which in turn prolongs patient suffering.[7][8][9] Treatment has changed very little over 30 years, leading to a resigned acceptance of suboptimal outcomes for patients.[10][11]

We’re committed to using emerging science to develop novel therapies for the treatment of severe mood disorders. New approaches to treatment are needed, which will offer an improved response in patients.


Breaking Depression

Breaking Depression aims to raise awareness of the challenges of living with different types of depression, including MDD, and provides practical tools to help everyone start the right conversations with their loved ones and healthcare professionals to get the right support. The campaign has been started by Janssen, with support from the Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe) and the European Federation of Associations of Families of People with Mental Illness (EUFAMI).

By broadening our understanding of the different types of depression, we can all work together to help break depression for good.

Pledge your support

The Little Book of Big Conversations

Developed in partnership with GAMIAN-Europe and EUFAMI, The Little Book of Big Conversations is a digital book containing practical advice to help people start conversations about depression.

Open and honest conversations about depression are an important step towards ensuring that people get the support they need. However, we understand that starting these conversations can be daunting and knowing where to begin can be difficult.

Open the book

Plan your way out of depression

Everyone’s route out of depression is different, however the journey can be more difficult if made alone. Seeking help and finding ways to cope with depression can be helpful in a person’s journey out of depression

Whatever route taken, supportive conversations with a doctor or another healthcare professional are often crucial. This is why we have partnered with GAMIAN-Europe and EUFAMI to create a free guide with practical tips to support people living with depression, and their caregivers, in getting the most out of each step in their journey.

Open your guide

Multiple sclerosis (MS)

MS is a chronic autoimmune inflammatory disease of the central nervous system, affecting over one million people in Europe.[12][13] The level of disability associated with the disease poses a unique human, societal and economic burden.[14][15]

MS comprises a range of both visible and invisible symptoms such as fatigue, emotional changes and cognitive problems, and there is no cure for MS.[16] Additionally, it is not always easy for people living with MS and their physicians to find a treatment which addresses all of their symptoms, so unmet needs remain.

Our goal is to address the life-long and life-limiting symptoms of MS. We recognise the invisible symptoms of MS are often an under-supported burden that people living with MS struggle with.


MS can be a complex disease, and at times it can feel confusing and overwhelming for those affected. That’s why we’ve created MoreToMS, a master patient engagement hub designed to support people living with MS, as well as friends and family members, through the variety of challenges that life with MS can bring.

In addition to providing valuable information to help people living with MS understand their condition, MoreToMS hosts a number of interactive tools and programmes that give practical solutions to everyday challenges, including the ExpressMS initiative (find more information on this below), a symptom management programme and a series of useful downloadable resources.

MoreToMS is here to support people affected by MS throughout their disease journey.

Find out more


Fatigue, emotional changes and cognitive impairment are just a few of the invisible symptoms experienced by those living with MS and can make it hard for them to express how they feel.[17]

In partnership with the MS community, we have created ExpressMS, an interactive ‘phase generator’ that can be used online or as an app to download on a mobile phone. The tool aims to provide people living with MS with new phrases to describe and express their invisible symptoms and encourage more meaningful conversations with their family, friends and healthcare professionals.

Understanding starts with a conversation. Together we can speak MS.

Find out more


Schizophrenia affects approximately 24 million people globally.[18] In Europe alone, it affects 3.7 million people and is among the leading causes of years lost due to disability.[19][20]

Without effective treatment, it is a persistent and detrimental condition that increases mortality and impacts more than just the patient.[21][22][23]

At Janssen, we’ve led the way in the development of simplified and innovative treatments for patients with schizophrenia. But the challenge of schizophrenia is not solved completely.